文献速递外周动脉疾病

DURABILITY髂动脉研究:自膨式支架治疗症状性外周动脉疾病的9个月结局

Nine-Month Outcomes of the DURABILITY Iliac Study on Self-Expanding Stents for Symptomatic Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2018-04-18

DURABILITY Iliac是一项前瞻性、多中心、核心实验室裁决的非随机临床研究,纳入美国和欧洲15个中心的75例受试者,评估2种镍钛合金自膨式支架治疗Rutherford 2-4级外周动脉疾病患者长度≤10 cm、狭窄>50%的髂总动脉和髂外动脉粥样硬化病变的安全性和有效性。9个月主要不良事件率为1.3%(1/75),9个月主要通畅率为95.8%,免于临床驱动的靶血管血运重建率为98.6%,器械成功率为100%。结论认为9个月结果证明这2种镍钛合金自膨式支架治疗髂总动脉和髂外动脉粥样硬化病变是安全有效的。

要点

  • 9个月主要不良事件率为1.3%(1/75),仅1例受试者发生临床驱动的靶病变血运重建。
  • 9个月主要通畅率为95.8%,免于临床驱动的靶血管血运重建率为98.6%。
  • 器械成功率为100%,30天和9个月时步行障碍问卷各分类评分均改善。

核心结论

  • DURABILITY Iliac研究的9个月结果证明2种镍钛合金自膨式支架治疗髂总动脉和髂外动脉粥样硬化病变是安全有效的。

研究设计与样本

  • DURABILITY Iliac是一项前瞻性、多中心、核心实验室裁决的非随机临床研究,纳入美国和欧洲15个中心的75例受试者。
  • 研究对象为Rutherford分级外周动脉疾病2-4级、髂总动脉和髂外动脉粥样硬化病变长度≤10 cm且狭窄>50%的受试者。
  • 临床随访在术后30天、9个月以及1年、2年和3年进行。

主要发现

  • 9个月主要不良事件率为1.3%(1/75),1例受试者发生临床驱动的靶病变血运重建;未报告围手术期死亡、心肌梗死或截肢。
  • 9个月主要通畅率为95.8%,9个月免于临床驱动的靶血管血运重建率为98.6%。
  • 30天和9个月随访时,受试者步行障碍问卷所有分类(步行障碍、步行速度、步行距离和爬楼梯)评分均改善。
  • 器械成功率为100%。

关键数值与推荐

  • 主要结局指标为9个月主要不良事件率,定义为围手术期死亡、院内心肌梗死、临床驱动的靶病变血运重建和截至术后9个月治疗肢体截肢的复合终点。
  • 次要结局包括9个月主要通畅率、临床驱动的靶血管血运重建、30天和9个月踝肱指数变化及步行障碍问卷评分变化。
  • 器械成功定义为能够按预期在治疗部位部署支架。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The DURABILITY Iliac clinical study evaluated the safety and effectiveness of 2 nitinol self-expanding stents for the treatment of atherosclerotic common and external iliac artery lesions up to 10 cm in length and >50% stenosis in subjects with Rutherford classification peripheral arterial disease stages 2-4. METHODS: DURABILITY Iliac was a prospective, multicenter, core lab adjudicated, nonrandomized clinical study enrolling 75 subjects from 15 sites in the United States and Europe. Clinical follow-up visits were at 30 days, 9 months, and 1, 2, and 3 years after procedure. The primary outcome measured was the major adverse event (MAE) rate at 9 months, defined as a composite of periprocedural death, in-hospital myocardial infarction (MI), clinically driven target lesion revascularization (CD-TLR), and amputation of the treated limb through 9 months after procedure. Secondary outcomes included primary patency rate at 9 months, clinically driven target vessel revascularization (CD-TVR), change in ankle-brachial index, and change in Walking Impairment Questionnaire score at 30 days and 9 months. Device success was defined as the ability to deploy the stent as intended at the treatment site. RESULTS: The MAE rate at 9 months was 1.3% (1/75), with 1 subject experiencing a CD-TLR. No periprocedural deaths, MIs, or amputations were reported. Primacy patency at 9 months was 95.8%. Freedom from CD-TVR was 98.6% at 9 months. Subjects improved in Walking Impairment Questionnaire scores for all categories (walking impairment, walking speed, walking distance, and stair climbing) at the 30-day and 9-month visit. Device success was 100%. CONCLUSIONS: The 9-month results of the DURABILITY Iliac study demonstrate the safety and effectiveness of 2 nitinol self-expanding stents for the treatment of atherosclerotic lesions of the common and external iliac arteries.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Faries P, Jaff M, Peeters P, et al. Nine-Month Outcomes of the DURABILITY Iliac Study on Self-Expanding Stents for Symptomatic Peripheral Artery Disease. Ann Vasc Surg. 2018. PMID: 29678649. doi:10.1016/j.avsg.2018.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。